On August 4, Nucleus Network announced the acquisition of Hammersmith Medicines Research (HMR) for an undisclosed price.
HMR specializes in early clinical trials for pharmaceutical and biotechnology companies worldwide. Founded in 1993, HMR is now the biggest contract research organization (CRO) of its kind in the United Kingdom and one of the biggest in Europe.
Melbourne-based Nucleus Network is the only early-phase clinical research provider with a global footprint, operating dedicated Phase I facilities in Australia, the United States and the United Kingdom.
“We are deeply honored by the trust Dr Boyce has placed in us to carry forward HMR’s legacy,” said Teena Pisarev, Chief Executive Officer of Nucleus Network. “This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered.”
According to data captured in the LevinPro HC database, this acquisition represents the 12th CRO deal of 2025. There were 33 CRO transactions announced during 2024, 44 announced during 2023 and 41 announced during 2022.
